Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Pear Therapeutics Developed reSET-A™ PDT Product Candidate for Alcohol Use Disorder (AUD)

Pear therapeutics developed new reSET-A™ PDT product candidate for the treatment of alcohol use disorder (AUD)

PDTsare new therapeutic class designed with software to directly treat disease. Similar to traditional medicines, PDT’s are developed and tested in a randomized controlledtrials and demonstrates safety and effectiveness.

Currently, there are few treatment options for AUD patients with less than 2 percent of patients receiving medication for treating AUD.There are no FDA approved prescribed digital therapeutics or medical devices available for people with AUD-only.

In U.S, alcohol is one of the most commonly consumed substance. According to the survey, it was stated that in the year 2019 around 14 million U.S population including adults aging 18 and older had AUD. Moreover, alcohol related problems has affected approximately 95,000 people’s life leading them to deaths and thus made alcohol as the third main leading cause of death in United States.

U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy designation for reSET-A™ PDT product candidateto treat alcohol use disorder (AUD).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024